Liver Cirrhosis Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight

(Albany, USA) DelveInsight's, "Liver Cirrhosis Pipeline Insight 2024" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Liver Cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Liver Cirrhosis Treatment Drugs @ Liver Cirrhosis Pipeline Outlook Report- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Liver Cirrhosis Pipeline Report
• In November 2024:- Intercept Pharmaceuticals- A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid.
• In November 2024:- Boehringer Ingelheim- Safety, Tolerability and Pharmacodynamics of BI 770371 Administered Intravenously in Patients With Compensated Cirrhosis Due to MASH: a Phase IIa, Multi-center, Randomized, Double-blind, Placebo-controlled Trial. This study is open to people with cirrhosis caused by a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). The purpose of this study is to find out how well a medicine called BI 770371 is tolerated.
• DelveInsight's Liver Cirrhosis pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Liver Cirrhosis treatment.
• The leading Liver Cirrhosis Companies includes CymaBay Therapeutics, Mirum Pharmaceuticals, Pharmicell Co., Ltd., Can-Fite BioPharma, Genfit, SHIONOGI & Co., COUR Pharmaceutical, Zydus Therapeutics Inc, Genkyotex SA, Gannex Pharma Co., Ltd., Novartis, HighTide Biopharma Pty Ltd, Chia Tai Tianqing Pharmaceutical Group Co.Ltd., GlaxoSmithKline, Ohara Pharmaceutical, Pliant Therapeutics, MYR Pharmaceuticals, Active Biotech, Future Medicine Co Ltd., Dr. Falk Pharma GmbH, Suzhou Zelgen Biopharmaceuticals, and others.
• Promising Liver Cirrhosis Pipeline Therapies includes IDN-6556, ADSCs, NGM282, Rifaximin SSD 40 mg IR tablet, Livercellgram, INT-747, Obeticholic Acid (OCA), and others.

Find out more about Liver Cirrhosis Therapeutics Assessment @ Liver Cirrhosis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

In the Liver Cirrhosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Liver Cirrhosis NDA approvals (if any), and product development activities comprising the technology, Liver Cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Liver Cirrhosis Overview
Liver cirrhosis is a condition in which the liver is scarred and permanently damaged, and scar tissue replaces healthy liver tissue, preventing the liver from working normally. Cirrhosis is usually caused by long-term liver damage from conditions such as alcohol-associated liver disease, nonalcoholic fatty liver disease, chronic hepatitis C, and chronic hepatitis B. Symptoms of cirrhosis may not appear until the liver is badly damaged and can include fatigue, severe itchy skin, and swelling in the legs and abdomen. Doctors diagnose cirrhosis based on medical history, a physical exam, and the results of tests such as blood tests, imaging tests, and liver biopsy.

Dive deep into rich insights for new drugs for Liver Cirrhosis Treatment, Visit @ Liver Cirrhosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Liver Cirrhosis Emerging Drugs Profile
• Elafibranor: Ipsen
Elafibranor (GFT-505) is under development for the treatment of colitis, non-alcoholic fatty liver disease, primary biliary cholangitis (PBC), and primary sclerosing cholangitis. The drug candidate is administered orally as a coated tablet. It acts by targeting peroxisome proliferator-activated receptor (PPAR) alpha and PPAR-beta / PPAR- delta. The drug candidate was under development for dyslipidemia, abdominal obesity, type 2 diabetes, Crohn's disease, insulin resistance and glucose intolerance, colitis and NAFLD/NASH-induced hepatocellular carcinoma (HCC). In December 2023, Ipsen and GENFIT announced that the US Food and Drug Administration (FDA) had accepted the New Drug Application (NDA) for investigational elafibranor.
• Volixibat: Mirum Pharmaceuticals
Volixibat is a minimally absorbed, orally administered investigational therapy designed to selectively inhibit ileal bile acid transporter (IBAT), a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company believes that volixibat may offer a novel approach in the treatment of rare liver diseases impacting both adults and children by blocking the recycling of bile acids, thereby reducing bile acids systemically. Volixibat is currently being studied in intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, and primary biliary cholangitis. Currently, the drug is in Phase II stage of its clinical trial.
• PVT201: Parvus Therapeutics
Parvus Therapeutics, a biopharmaceutical company developing PVT201 drug for the treatment of Primary Biliary Cholangitis. Currently, the drug is in preclinical stage of its development.

Liver Cirrhosis Therapeutics Assessment
There are approx. 45+ key Liver Cirrhosis companies which are developing the Liver Cirrhosis therapies. The Liver Cirrhosis companies which have their Liver Cirrhosis drug candidates in the most advanced stage, i.e. phase III include, Ipsen.

DelveInsight's Liver Cirrhosis pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Liver Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Liver Cirrhosis Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
For further information on the Liver Cirrhosis Pipeline therapeutics, reach out to Liver Cirrhosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Liver Cirrhosis Pipeline Report
• Coverage- Global
• Liver Cirrhosis Companies- CymaBay Therapeutics, Mirum Pharmaceuticals, Pharmicell Co., Ltd., Can-Fite BioPharma, Genfit, SHIONOGI & Co., COUR Pharmaceutical, Zydus Therapeutics Inc, Genkyotex SA, Gannex Pharma Co., Ltd., Novartis, HighTide Biopharma Pty Ltd, Chia Tai Tianqing Pharmaceutical Group Co.Ltd., GlaxoSmithKline, Ohara Pharmaceutical, Pliant Therapeutics, MYR Pharmaceuticals, Active Biotech, Future Medicine Co Ltd., Dr. Falk Pharma GmbH, Suzhou Zelgen Biopharmaceuticals, and others.
• Liver Cirrhosis Pipeline Therapies- IDN-6556, ADSCs, NGM282, Rifaximin SSD 40 mg IR tablet, Livercellgram, INT-747, Obeticholic Acid (OCA), and others.
• Liver Cirrhosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Liver Cirrhosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover more about Liver Cirrhosis Drugs in development @ Liver Cirrhosis Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Liver Cirrhosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Liver Cirrhosis - DelveInsight's Analytical Perspective
7. Late Stage Products (Registered)
8. Elafibranor: Ipsen
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Volixibat: Mirum Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Preclinical Stage Products
16. PVT201: Parvus Therapeutics
17. Inactive Products
18. Liver Cirrhosis - Collaborations Assessment- Licensing / Partnering / Funding
19. Liver Cirrhosis - Unmet Needs
20. Liver Cirrhosis - Market Drivers and Barriers
21. Appendix

Trending Reports:
• Ehlers-danlos Syndrome Market: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Surgical Site Infections Market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infection-absssi-market-insights-epidemiology-and-market-forecast
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Alpha Antitrypsin Market: https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-a1atd-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Chronic Rhinosinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/intracranial-stents-market
• Pcsk9 Inhibitor Market: https://www.delveinsight.com/report-store/pcsk9-inhibitors-psck9i-market
• Continuous Renal Replacement Therapy Machines Market: https://www.delveinsight.com/report-store/continuous-renal-replacement-therapy-machines-market
• Hypoparathyroidism Market: https://www.delveinsight.com/report-store/hypoparathyroidism-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Neurovascular Thrombectomy Devices Market: https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
• Epithelial Ovarian Cancer Market: https://www.delveinsight.com/report-store/ovarian-cancer-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/rare-diseases

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.